Up-to-date Trial for PSMA-Targeted Treatments in Metastatic Prostate Cancer Excites
The investigational radiolabeled lightweight molecule that targets prostate-specific membrane layer antigen (PSMA), lutetium-177 PSMA-617 (LuPSMA), conferred a high responses speed
Read more